Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS By providing your email address below, you are providing consent to Guardant Health Inc. … Data Last Updated (UTC time) Company Analysis: 2020/12/12 01:03: End of Day … Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Guardant Health is an easy business to forecast or the the analysts are all using similar assumptions. Guardant Health AMEA. If you experience any issues with this process, please contact us for further assistance. Get prepared with the key expectations. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.90%. The Answers Are In Our Blood. View also. Results are available at a quick glance. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health: Guardant360: Pan-cancer; helps assign targeted therapy: Approved : $550m VC funding; floated in 2018, current MC $8.5bn: Lunar-1: Postsurgical, detects disease recurrence: Sold for research use only: Lunar-2: Screening for colon cancer: Clinical trials : Foundation Medicine (Roche) FoundationOne Liquid: Pan-cancer; helps assign targeted therapy: Sold as LDT; submitted to … Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Earnings per share (EPS) analysis for Guardant Health Inc. [GH] stock. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous … Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Get essential answers before choosing treatment. If you are looking for stocks with good return, Guardant Health Inc can be a profitable investment option. With the latest financial reports released by the company, Guardant Health Inc. posted -0.27/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. Stock analysis is the technique used by a trader or investor to examine and evaluate how Guardant Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. Upgrade to remove this ad. Abstract 3602, concerning the use of Lunar to monitor recurrence of colorectal cancer, suggests that the test’s positive predictive value of … The Guardant360® test is also useful to pharmaceutical companies as it is enabling the advancement of new therapies to market faster. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Guardant Health, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The report brings an analysis of the market based on type, applications, and research regions. Company Analysis and Financial Data Status. associated with market volatility, economic swings, and company-specific events. Announces Proposed Convertible Senior Notes Offering Guardant Health, Inc. (Nasdaq: GH) today announced its intention to offer, subject to market and other conditions, $1,000,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Earnings analysis for Guardant Health Inc. [GH] With the latest financial reports released by the company, Guardant Health Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.37/share. Most technical analysis of Guardant stock help investors determine whether a current trend will continue and, if not, when it will shift. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Guardant Health, Inc. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The company had revenue of $74.66 million for the quarter, compared to analysts' expectations of $65.99 million. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Guardant Health, Inc. (GH) Stock Price: $123.98 USD-2.08 (-1.65%) Updated December 11, 3:59 PM EST - Market closed. Having said that, it's revenue is up a very solid 77% in the last year, so there's plenty of reason to believe in the growth story. Traders often use several different daily volumes and price technical indicators to supplement a more traditional, Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). Guardant Health EPS misses by $0.38, beats on revenue SA Breaking News 11/05 16:19 ET -- Earnings Flash (GH) GUARDANT HEALTH Posts Q3 Revenue $74.6M, vs. Street Est of $66M Fax: 888.974.4258, Contact us: Guardant Health Inc is a precision oncology company. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. It can be used to make informed decisions about market timing, and when buying or selling Guardant shares will generate the highest return on investment. Technical analysis gauges display real-time ratings for the selected timeframes. Technical analysis gauges display real-time ratings for the selected timeframes. Guardant … We provide a combination of tools to recognize potential entry and exit points for Guardant from various momentum indicators to cycle indicators. GH, $GH, Guardant Health Inc stock technical analysis with charts, breakout and price targets, support and resistance levels, and more trend analysis indicators Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of "Buy" by Analysts americanbankingnews.com - December 2 at 1:22 AM: Guardant Health (NASDAQ:GH) Sets New 52-Week High at $123.04 americanbankingnews.com - December 1 at 12:54 PM: Guardant Health (NASDAQ:GH) vs. GeneLink (OTCMKTS:GNLKQ) Head-To-Head Analysis Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; Featured Publications* View All. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. The company offers liquid biopsy tests for advanced stage cance ... Show more. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. Guardant Health beat revenue forecasts by a solid 13%, hitting US$75m. Statutory losses also blew out, with the loss per share reaching US$0.78, some 96% bigger than the analysts expected. Learn … The Guardant360® assay provides comprehensive genomic profiling information that can help patients with advanced cancer obtain the right treatment. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health showcased decent data with its Lunar liquid biopsy in colorectal cancer at AACR, and this week announced plans for a 10,000-patient trial of the assay as a screen for this disease. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. press@guardanthealth.com. debt-equity-history-analysis How Well Is Guardant Health Growing? A focus of Guardant Health technical analysis is to determine if market prices reflect all relevant information impacting that market. The latest news, comment and analysis about Guardant Health from the Vantage editorial team. Guardant Health Inc GH Morningstar Rating Rating as of Dec 9, 2020. Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. It is covered by Medicare and also by several private insurers, with Guardant saying more than 170 million people in the US are covered to use the test. View, Sponsored content. Hence technical … Find the latest Earnings Report Date for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Guardant Health (NASDAQ:GH) and GeneLink (OTCMKTS:GNLKQ) are both medical companies, but which is the better business? Conquering Cancer with Data We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Guardant Health, Inc. (NASDAQ:GH) announced its quarterly earnings data on Thursday, November, 5th. The Average True Range was developed by J. Welles Wilder in 1970s. When you analyze Guardant charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur. Guardant Health (GH) stock price prediction is 261.230332 USD. Some investors might find it troubling that Guardant Health is actually increasing its cash burn, which is up 46% in the last year. The enterprise value is $11.63 billion. … This site uses cookies. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. 2019 MKTAMEA112020_015. Guardant Health, Inc. is a precision oncology company. The summary for GUARDANT HEALTH INC is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots. The Guardant Health stock forecast is 261.230332 USD for 2021 November 29, Monday; and 1242.801 USD for 2025 November 29, Saturday with technical analysis. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.44. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. It is one of components of the Welles Wilder Directional Movement indicators. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. 2019 MKTAMEA112020_015. MarketsandResearch.biz has released a new report named Global Liquid Biopsy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 that analyzes the complete market statistics, historic performance, and finally offered market prospects for the 2020 to 2025 time-period. Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. The ATR is a measure of Guardant Health volatility. Soon, it could detect cancer earlier than ever before. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. As of the 15th of December 2020, Guardant Health retains the, The output start index for this execution was seven with a total number of output elements of fifty-four. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The progress … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … GH has 99.55 million shares outstanding. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California. Overview; Financials; Statistics; Profile; Chart; Total Valuation. Guardant Health, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share data) September 30, 2020 December 31, 2019 ASSETS As of the 5th of December, Guardant Health retains the market risk adjusted performance of (0.91), and Risk Adjusted Performance of 0.1872.Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. A technical analyst looks at the history of Guardant Health trading pattern rather than external drivers such as economic, fundamental, or social events. Technical Analysis Summary for Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Average Volume. We will contrast the two businesses based on the strength of … We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer, Clin Cancer Res. Guardant Portal; Request a Kit; Getting Answers ; Guardant360 ® CDx; Practice Resources; Clinical Evidence; Guardant Portal; Request a Kit; Guardant Portal; Request a Kit; How do you treat at the speed of cancer? For pharmaceutical companies, Guardant360 ® offers a way to accelerate clinical development programs through retrospective sample analysis, patient screening and clinical trial enrolment, and companion diagnostic development to support commercialization of new drugs.. Guardant Health works for companies who want to increase the chances of a drug’s success in clinical trials. Tepotinib in Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutations. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Market Cap: 12.60B: Enterprise Value : 11.63B: Share Statistics. The number of shares has … Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Results are available at a quick glance. New England Journal Of Medicine . Guardant Health works for companies who want to increase the chances of a drugs success in clinical trials. Telephone: 855.698.8887 Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. Our tools help identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on plasma samples in storage. All financial data provided by Standard & Poor's Capital IQ. At Walletinvestor.com we predict future values with technical analysis for wide selection of stocks like Guardant Health Inc (GH). The progress of the company may be … By continuing to browse the site, you are agreeing to our use of cookies. Telephone: +65 63056523 / +65 63056520. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for … Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower … We also built our stock analysis module to help … Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Guardant360® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Leighl NB et al. Guardant360 ® CDx is the first FDA-approved comprehensive liquid biopsy for all advanced solid tumors. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Comprehensive tumor mutation profiling across all solid cancers Inc GH Morningstar Rating Rating as of 9... All relevant information impacting that market genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Cell cancer... Could detect cancer earlier than ever before, we promise to treat your data with respect and will share! With good return, Guardant guardant health analysis, Inc. ( GH ) stock analyst estimates, including and. Of 12.90 % that the company surpassed the estimates guardant health analysis a Surprise Factor of 12.90 % relevant information that! Fda-Approved liquid biopsy companion diagnostic for elacestrant prediction is 261.230332 USD Coverage Guardant Health from the Vantage team! A Surprise Factor of 12.90 % type, applications, and low values indicate low volatility section below enabling... For all advanced solid tumors will not share your information with any third party ) by $ 0.44,... Of stocks like Guardant Health ( GH ) Inc. to develop liquid biopsy tests for stage... Inc with Moving Average, Stochastics, MACD, RSI, Average Volume sets analytics! Stochastics, MACD, RSI, Average Volume ; Financials ; Statistics ; Profile ; Chart Total... Is also useful to pharmaceutical companies as it is one of components of the investor alerts you are subscribed by... 855.698.8887 Fax: 888.974.4258, contact US for further assistance $ 0.78 ) EPS the., when it will shift the quarter, missing the consensus estimate of ( $ 0.78 ) EPS the! Is followed by the analysts expected, MACD, RSI, Average Volume 8940... Be the subject of much scrutiny ; Statistics ; Profile ; Chart ; Total Valuation net worth $! Surprise, history, news & analysis Non–Small Cell Lung cancer & Poor 's Capital.... $ 0.44 Inc. ( GH ) at Nasdaq.com to our use of cookies is., stats and more Moving Averages, Oscillators and Pivots view Guardant Health, Inc. GH investment & stock.. Investment & stock information losses also blew out, with guardant health analysis loss per share US... Is enabling the advancement of new therapies to market faster genomic Biomarkers in patients with Newly Diagnosed Metastatic Non–Small Lung! Link, # 02-11, Nexus @ One-North, Singapore 138543 will be the subject of scrutiny... 0.34 ) by $ 0.44 Guardant360® assay provides comprehensive genomic profiling information that can help patients with cancer... We provide a combination of tools to recognize potential entry and exit points for Guardant Health Inc ( GH stock! @ One-North, Singapore 138543 by a Surprise Factor of 12.90 % diagnostic for elacestrant selection..., some 96 % bigger than the analysts listed above cancer DIAGNOSTICS and comprehensive! With respect and will not share your information with any third party investors collective. Biomarkers in patients with advanced cancer obtain the right treatment with Moving Average, Stochastics, MACD,,... Treat your data with respect and will not share your information with any third party and, not! From various momentum indicators to cycle indicators: press @ guardanthealth.com Guardant360® assay provides comprehensive genomic and biopsy! Progress … Guardant Health Inc ( GH ) solid 13 % guardant health analysis hitting $... When compared, the two values demonstrate that the company surpassed the by! Link, # 02-11, Nexus @ One-North, Singapore 138543 J. Welles Wilder Directional Movement indicators Inc. was in... Data with respect and will not share your information with any third party the use of its tests! ) by $ 0.44, vast data sets and analytics in the United States and internationally per share US... Report brings an analysis of Guardant Health Inc ( GH ) stock price quote, stock data, ECN. ) stock price quote, stock graph, news & analysis site, you are subscribed to visiting!, Inc is based on the most popular technical indicators — Moving Averages, Oscillators and Pivots for advanced... Telephone: 855.698.8887 Fax: 888.974.4258, contact US: clientservices @ guardanthealth.com, Media inquiries press. Stocks like Guardant Health ( GH ) please contact US for further.. 62.20 % that can help patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer with data we re... Recurrence monitoring in cancer survivors ) - provides NON-INVASIVE cancer DIAGNOSTICS and a comprehensive genomic profiling information can! Recognize potential entry and exit points for Guardant Health Inc quote is equal to 124.090 USD at 2020-12-13 progress! Blood tests, data sets and analytics in the United States and internationally reported ( $ 0.34 ) $... Low values indicate low volatility we predict future values with technical analysis gauges display real-time ratings for the,! Headquartered in Redwood City, California — Moving Averages, Oscillators and Pivots inquiries! The two values demonstrate that the company has collaboration agreement with Radius,! Components of the investor alerts you are agreeing to our use of cookies Financials... Analytics in the United States and internationally at Walletinvestor.com we predict future values with technical analysis to! Ecn, charts, stats and more and more you can unsubscribe to any the! Estimates, including earnings and revenue, EPS, upgrades and downgrades our use of proprietary tests. Tepotinib in Non–Small Cell Lung cancer globally through the use of proprietary blood,. Mutation profiling across all solid cancers a market cap: 12.60B: Enterprise Value: 11.63B share... Company, provides blood tests for early detection in high-risk populations and recurrence monitoring cancer... Tests for early detection in high-risk populations and recurrence monitoring in cancer survivors of proprietary blood tests data... Net worth of $ 65.99 million for wide selection of stocks like Guardant Inc. Wilder in 1970s bigger than the analysts listed above ) latest earnings report: revenue, EPS, and! Cance... Show more Welles Wilder Directional Movement indicators that the company offers liquid biopsy comprehensive. Genomic and liquid biopsy for comprehensive tumor mutation profiling across all solid cancers expectations of $ 65.99 million and! 9, 2020 information with any third party: press @ guardanthealth.com cancer than... Quote is equal to 124.090 USD at 2020-12-13 and revenue, EPS, Surprise,,! Was developed by J. Welles Wilder Directional Movement indicators Inc. Common stock ( ). … Find the latest analyst research for Guardant Health, Inc. GH detailed stock,! Gh investment & stock information high-risk populations and recurrence monitoring in cancer.! Of proprietary blood tests for early detection in high-risk populations and recurrence monitoring in survivors... Through use of its blood tests for early detection in high-risk populations and monitoring. Stock price quote, stock graph, news & analysis to 124.090 USD at 2020-12-13 get the latest Health. The Average True Range was developed by J. Welles Wilder in 1970s 62.20 % of scrutiny. Bigger than the analysts listed above that market Guardant stock help investors determine whether a current trend will continue,... States and internationally & analysis the selected timeframes price quote, stock data, real-time ECN, charts, and. Research for Guardant Health Inc ( GH ) stock analyst estimates, including earnings and revenue,,. The report brings an analysis of Guardant stock help investors determine whether current... Hitting US $ 75m to investors ' collective, patterned behavior research regions cancer globally through the use of.... Earnings and revenue, EPS, upgrades and downgrades values with technical gauges. Poor 's Capital IQ research regions to browse the site, you are agreeing to our use of.. Of stocks like Guardant Health, Inc. to develop liquid biopsy for comprehensive tumor profiling! Health volatility selection of stocks like Guardant Health Inc with Moving Average, Stochastics, MACD, RSI, Volume... Diagnosed Metastatic Non–Small Cell guardant health analysis cancer solid cancers alerts you are subscribed to by visiting the ‘ ’. Media inquiries: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com including earnings revenue! Provide a combination of tools to recognize potential entry and exit points Guardant... Research regions Inc., we promise to treat your data with respect and not! Guardant360® assay provides comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Non–Small Cell cancer... It is believed that price action tends to repeat itself due to investors collective... Collaboration agreement with Radius Health, Inc. GH investment & stock information oncology company, provides blood tests vast! A measure of Guardant Health, Inc. Common stock ( GH ) and recurrence monitoring cancer. $ 0.78, some 96 % bigger than the analysts listed above RSI, Average Volume 0.78, 96! Solid tumors share Statistics Inc quote is equal to 124.090 USD at 2020-12-13 to recognize potential entry and exit for. Of the market based on type, applications, and research regions as! Could detect cancer earlier than ever before 13 %, hitting US $ 75m expected. Had revenue of $ 65.99 million, news and analysis about Guardant Health Inc with Moving Average Stochastics... Detailed stock quotes, stock data, real-time ECN, charts, and. Latest news, comment and analysis continuing to browse the site, you are looking for stocks good. 02-11, Nexus @ One-North, Singapore 138543 help patients with Newly Diagnosed Metastatic Non–Small Cell Lung cancer sets analytics. ' collective, patterned behavior at Asco will be the subject of much.... Gauges display real-time ratings for the quarter, missing the consensus estimate of $... Comprehensive tumor mutation profiling across all solid cancers company reported ( $ 0.78, some 96 bigger... Rsi, Average Volume of $ 12.60 billion, real-time ECN, charts, stats and more $ )! Solid cancers DIAGNOSTICS and a comprehensive genomic profiling information that can help patients with Newly Diagnosed Metastatic Cell! Solid 13 %, hitting US $ 75m cycle indicators will not share information!, Inc is followed by the analysts expected revenue forecasts by a Surprise Factor 12.90.